Omidenepag

File:Omidenepag.svg
Systematic (IUPAC) name
Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
Clinical data
Trade names	Eybelis, Omlonti
Legal status	US: ℞-only Rx-only
Routes of administration	Topical eye drops
Identifiers
CAS Number	1187451-41-7
ATC code	S01EX06 (WHO)
PubChem	CID: 44230575
DrugBank	DB15071
ChemSpider	44210451
UNII	Z95F9F9LU4
KEGG	D10965
ChEMBL	CHEMBL3707245
Synonyms	UR-7276, DE-117
Chemical data
Formula	C26H28N6O4S
Molecular mass	520.61 g·mol−1
SMILES CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1
InChI InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31) Key:YHGSTSNEOJUIRN-UHFFFAOYSA-N

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.

Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.

Medical uses

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.

Adverse effects

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.

Pharmacology

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. Omidenepag is a selective prostaglandin E2 receptor agonist.

History

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.